Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 10/20 | 0.64 |
| ▸ | PDE4A | P27815 | 10/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 9/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 5/20 | 0.50 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.43 |
| ▸ | PDE2A | O00408 | 1/20 | 0.43 |
| ▸ | PDE8B | O95263 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1536503 | 0.81 | PDE1B (0.48) | PDE4BPDE4DPDE1BPDE2APDE8B | |
| SCHEMBL4369695 | 0.80 | PDE4B (0.67) | PDE4BPDE4APDE4DPDE4CPDE1B | |
| SCHEMBL7446753 | 0.80 | PDE4B (0.67) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL4371694 | 0.80 | PDE4B (0.64) | PDE4BPDE4APDE4DPDE4CPDE1B | |
| SCHEMBL4368584 | 0.79 | PDE4B (0.83) | PDE4BPDE4APDE4DPDE4CPDE1B | |
| SCHEMBL13624574 | 0.78 | PDE4B (1.00) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL4366179 | 0.78 | PDE4B (0.74) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL15647758 | 0.76 | KMT2A (0.46) | PDE4BPDE4DPDE1BPDE2APDE8B | |
| SCHEMBL4370781 | 0.73 | PDE4B (0.75) | PDE4BPDE4APDE4DPDE4C | |
| SCHEMBL1536502 | 0.73 | CYP19A1 (0.49) | PDE4DPDE1BPDE2APDE8BADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | KALYPSYS, INC. (US) | 2009-11-26 | — | — | US | disclosed |
| WO-2008006052-A2 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | GOVEK STEVEN P (US) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291950-A1 | BICYCLIC HETEROARYL INHIBITORS OF PDE4 | PDE4A, PDE4B, PDE4C | PDE4B 2/4885PDE4A 1/4885PDE4D 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.